Overview
The 23rd DIA Japan Annual Meeting 2026 will be held at Tokyo Big-Sight from October 18 to 20, 2026.
The theme of this meeting is:
“Crossing Boundaries, Shaping a Future Beyond Imagination with Innovation.”
Today, the fields of healthcare and pharmaceutical development are undergoing a transformation of unprecedented proportions. Rapid advances in digital technologies and AI, diversification of drug discovery and development models, open innovation, regulatory reforms, patient-centric approaches, engagement of diverse stakeholders, and the pursuit of sustainability and social value are all progressing simultaneously—ushering in an era of change unlike any before.
Traditionally, medicine and healthcare have been confined to biological and chemical domains. In recent years, however, collaboration with engineering and IT has accelerated, and integration with human and social sciences—such as addressing ELSI (ethical, legal, and social issues)—has become indispensable.
The concept of “Neue Kombinationen” (literally "new combination", rendered as "innovation"), proposed by economist Joseph Schumpeter, refers not merely to invention or technological innovation, but to the creative act of combining existing elements in new ways. Such “new combinations” drive discontinuous change—what Schumpeter called “creative destruction”—bringing new value to society and industry.
In today’s world, connecting knowledge and technologies across disciplines through “innovation ” is more critical than ever. While AI has dramatically improved the efficiency of information processing and output, what AI generates remains an extension of existing knowledge and patterns. Therefore, creative attempts to combine existing elements in unprecedented ways represent a uniquely human endeavor—one that may hold the key to shaping the future in the AI era.
At the 23rd DIA Japan Annual Meeting, we aim to create a forum where participants from diverse fields, roles, organizations, and countries come together to explore possibilities beyond imagination through “innovation” born of interdisciplinary collaboration. We hope that each participant will bring their expertise and experience, engage in discussion and cooperation across disciplines, and seize this opportunity to open new horizons in healthcare and pharmaceutical development.
Program Committee
-
Haruko Yamamoto, MD, PHD Executive Director
National Cerebral and Cardiovascular Center, Japan -
Miyoko Yamauchi Head, Human Capital Development Group
CHUGAI PHARMACEUTICAL CO., LTD., Japan -
Kasumi Daidoji, PHD, RPH Associate Director, Clinical Planning & Development Dept., Medical Headquarters
Eisai Company, Ltd., Japan -
Kei Fukuhara, MSC Manager, Clinical Pharmacology
Pfizer R&D Japan, Japan -
Akiko Ikeda, RPH PRIMO, External Researcher/Consultant
National Cancer Center, Japan -
Masanari Jinnouchi CEO
Peaceful Co., Ltd., Japan -
Masaaki Jitsu
Bayer Yakuhin Ltd, Japan -
Hiroyuki Kanoh Senior Adviser, Laboratory & Office Group
MITSUI FUDOSAN Co., LTD, Japan -
Keiko Katsui, PHD Division of Biomedical Ethics and Social Co-Creation
Japan Agency for Medical Research and Development (AMED), Japan -
Keiji Kido Associate director, Global Patients Safety and Solutions
ELi Lilly Japan K.K., Japan -
Takashi Kimura, MS Clinical Operation
Pfizer R&D Japan G.K., Japan -
Kentaro Kogushi, PHD Head of Clinical Development Neurology-Psychiatry, Japan Development
AbbVie GK, Japan -
Suguru Komenoi Chief Reviewer, Offic of New Drug V
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Noriyuki Kozawa Deputy Coordination Director, Office of Medical Informatics and Science
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Misato Kuwagaki, MS Associate Director, Japan Data Sciences, Medical Sciences
Eli Lilly Japan K.K., Japan -
Ayano Miyake Research Management
St. Lukes International Hospital, Japan -
Hiroki Nagahama, MS Director, Japan Safety Risk Management Lead, Clinical Safety & Pharmacovigilance
GlaxoSmithKline K.K., Japan -
Takashi Nagakubo, PHD Principal Statistician, Biostatistics
Glaxosmithkline K.K., Japan -
Yukiko Nishimura, PHD, MSC Director
Advocacy Service for Rare and Intractable Diseases, Japan -
Tomohiro Obana CRA Line Manager, Clinical Operation
PPD SNBL, Japan -
Ai Okazaki, MT Health Science Research & Development Center
Institute of Science Tokyo Hospital, Japan -
Chiharu Onozaki Manager
EPS International Holdings Co., Ltd., Japan -
Yuki Sasaki Clinical Research Coordinator
Hokkaido University Hospital, Japan -
Marie Shiga
Pfizer Japan Inc., Japan -
Keisuke Suzuki, PHD Director, Innovation Center for Translational Research
National Center for Geriatrics and Gerontology, Japan -
Akiko Tamamori Clinical Study Manager, Clinical Study Management Dept.
Chugai Pharmaceutical Co., Ltd., Japan -
MICHIYO TANI Vice President
Planisware K.K., Japan -
Naoyuki Yabana, PHD Director, Office of Medical Devices I, Medical Devices Unit
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Manabu YANAGISAWA, PHD Deputy General Manager,Clinical Research and Development Division, Development R
Mochida Pharmaceutical Co., Ltd., Japan -
Hiroto Asou Reviewer, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Masahisa Kamikura Pharmacist, Data Management Section/Data Management Division, Clinical Research
National Cancer Center Hospital, Japan -
Yusho Kubota Oncology Clinical Development Department II
A2 Healthcare Corporation, Japan -
Eri Matsunaga R&D Quality Group, R&D & PV Quality Assurance Department
Daiichi Sankyo Co., Ltd., Japan -
Hideto Minohara T-CReDO
University of Tsukuba Hospital, Japan -
Eri Toyoshima
ZeeDia life science, Japan -
Shinya Watanabe Reviewer (Epidemiology)
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Yukihiro Matsuda, MSC Director of Project Management
Linical Japan, Japan -
Keiko Tsumori, MSC Associate Principle Scientist, Medical Writing, Regulatory Affairs Area, Japan D
MSD K.K., Japan -
Mitsuhiro Niimi, PHD Vice President & Managing Director, Japan
DIA, Japan
Have an account?